GABA(A) receptor alpha1 subunit deletion prevents developmental changes of inhibitory synaptic currents in cerebellar neurons.
Developmental changes in miniature IPSC (mIPSC) kinetics have been demonstrated previously in cerebellar neurons in rodents. We report that these kinetic changes in mice are determined primarily by developmental changes in GABA(A) receptor subunit expression. mIPSCs were studied by whole-cell recordings in cerebellar slices, prepared from postnatal day 11 (P11) and P35 mice. Similar to reports in granule neurons, wild-type cerebellar stellate neuron mIPSCs at P11 had slow decay kinetics, whereas P35 mIPSCs decayed five times faster. When mIPSCs in cerebellar stellate neurons were compared between wild-type (+/+) and GABA(A) receptor alpha1 subunit-deficient (-/-) littermates at P35, we observed dramatically slower mIPSC decay rates in -/- animals. We took advantage of the greater potency of imidazopyridines for GABA current potentiation with alpha1 subunit-containing receptors to characterize the relative contribution of alpha1 subunits in native receptors on inhibitory synapses of cerebellar granule neurons. Zolpidem-induced prolongation of mIPSC decay was variable among distinct cells, but it increased during development in wild-type mice. Similarly, Zolpidem prolongation of mIPSC decay rate was significantly greater in adult +/+ mice than in knock-outs. We propose that an increased alpha1 subunit assembly in postsynaptic receptors of cerebellar inhibitory synapses is responsible for the fast inhibitory synaptic currents that are normally observed during postnatal development.
Vicini
S
S
Department of Physiology and Biophysics, Georgetown University Medical School, Washington, DC 20007, USA. svicin01@georgetown.edu
Ferguson
C
C
Prybylowski
K
K
Kralic
J
J
Morrow
A L
AL
Homanics
G E
GE
D000818:Animals; D002478:Cells, Cultured; D002531:Cerebellum / Q000166:cytology / Q000187:drug effects / Q000254:growth & development / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D018755:GABA Agonists / Q000494:pharmacology; D058785:GABA-A Receptor Agonists; D017353:Gene Deletion; D066298:In Vitro Techniques; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D051379:Mice; D008815:Mice, Inbred Strains; D018345:Mice, Knockout; D008822:Mice, Transgenic; D009433:Neural Inhibition / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D018408:Patch-Clamp Techniques; D021122:Protein Subunits; D011725:Pyridines / Q000494:pharmacology; D011963:Receptors, GABA-A / Q000172:deficiency* / Q000235:genetics / Q000378:metabolism; D013234:Stem Cells / Q000166:cytology / Q000378:metabolism; D009435:Synaptic Transmission / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D000077334:Zolpidem
D018755:GABA Agonists; D058785:GABA-A Receptor Agonists; D021122:Protein Subunits; D011725:Pyridines; D011963:Receptors, GABA-A; D000077334:Zolpidem